Sangamo Therapeutics CFO Prathyusha Duraibabu resigns, effective Oct 1, 2025

SANGAMO THERAPEUTICS, INC

Duraibabu resigns to become senior leader at a private AI company; not due to any disagreement with Sangamo.
She will transition to part-time employment and remain interim principal financial officer until a successor is appointed.
Company thanks Duraibabu for contributions to strategic collaborations and investment allocations positioning Sangamo as a neurology-focused genomic medicines company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.